BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38342782)

  • 21. Prediction of vascular involvement and resectability by multidetector-row CT versus MR imaging with MR angiography in patients who underwent surgery for resection of pancreatic ductal adenocarcinoma.
    Lee JK; Kim AY; Kim PN; Lee MG; Ha HK
    Eur J Radiol; 2010 Feb; 73(2):310-6. PubMed ID: 19070981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is Pancreatic Head Cancer with Portal Venous Involvement Really Borderline Resectable? Appraisal of an Upfront Surgery Series.
    Ohgi K; Yamamoto Y; Sugiura T; Okamura Y; Ito T; Ashida R; Aramaki T; Uesaka K
    Ann Surg Oncol; 2017 Sep; 24(9):2752-2761. PubMed ID: 28685356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bounding box-based 3D AI model for user-guided volumetric segmentation of pancreatic ductal adenocarcinoma on standard-of-care CTs.
    Mukherjee S; Korfiatis P; Khasawneh H; Rajamohan N; Patra A; Suman G; Singh A; Thakkar J; Patnam NG; Trivedi KH; Karbhari A; Chari ST; Truty MJ; Halfdanarson TR; Bolan CW; Sandrasegaran K; Majumder S; Goenka AH
    Pancreatology; 2023 Aug; 23(5):522-529. PubMed ID: 37296006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor-Vessel Relationships in Pancreatic Ductal Adenocarcinoma at Multidetector CT: Different Classification Systems and Their Influence on Treatment Planning.
    Zaky AM; Wolfgang CL; Weiss MJ; Javed AA; Fishman EK; Zaheer A
    Radiographics; 2017; 37(1):93-112. PubMed ID: 27885893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DeepPrognosis: Preoperative prediction of pancreatic cancer survival and surgical margin via comprehensive understanding of dynamic contrast-enhanced CT imaging and tumor-vascular contact parsing.
    Yao J; Shi Y; Cao K; Lu L; Lu J; Song Q; Jin G; Xiao J; Hou Y; Zhang L
    Med Image Anal; 2021 Oct; 73():102150. PubMed ID: 34303891
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Automated Artificial Intelligence Model Trained on a Large Data Set Can Detect Pancreas Cancer on Diagnostic Computed Tomography Scans As Well As Visually Occult Preinvasive Cancer on Prediagnostic Computed Tomography Scans.
    Korfiatis P; Suman G; Patnam NG; Trivedi KH; Karbhari A; Mukherjee S; Cook C; Klug JR; Patra A; Khasawneh H; Rajamohan N; Fletcher JG; Truty MJ; Majumder S; Bolan CW; Sandrasegaran K; Chari ST; Goenka AH
    Gastroenterology; 2023 Dec; 165(6):1533-1546.e4. PubMed ID: 37657758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
    Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
    Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreas CT assessment for pancreatic ductal adenocarcinoma resectability: effect of tube voltage and slice thickness on image quality and diagnostic performance.
    Lee DH; Lee SS; Lee JM; Choi JY; Lee CH; Ha HI; Kang BK; Yu MH; Chang W; Park SJ
    Cancer Imaging; 2023 Dec; 23(1):126. PubMed ID: 38111054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy:
    Soloff EV; Al-Hawary MM; Desser TS; Fishman EK; Minter RM; Zins M
    AJR Am J Roentgenol; 2022 Apr; 218(4):570-581. PubMed ID: 34851713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preoperative CT Classification of the Resectability of Pancreatic Cancer: Interobserver Agreement.
    Joo I; Lee JM; Lee ES; Son JY; Lee DH; Ahn SJ; Chang W; Lee SM; Kang HJ; Yang HK
    Radiology; 2019 Nov; 293(2):343-349. PubMed ID: 31502935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT.
    Morgan DE; Waggoner CN; Canon CL; Lockhart ME; Fineberg NS; Posey JA; Vickers SM
    AJR Am J Roentgenol; 2010 Mar; 194(3):615-22. PubMed ID: 20173136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of resectability of pancreatic cancer using novel immersive high-performance virtual reality rendering of abdominal computed tomography and magnetic resonance imaging.
    Kunz JM; Maloca P; Allemann A; Fasler D; Soysal S; Däster S; Kraljević M; Syeda G; Weixler B; Nebiker C; Ochs V; Droeser R; Walker HL; Bolli M; Müller B; Cattin P; Staubli SM
    Int J Comput Assist Radiol Surg; 2024 Jan; ():. PubMed ID: 38252362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quantifying vascular invasion in pancreatic cancer-a contrast CT based method for surgical resectability evaluation.
    Lao Y; David J; Fan Z; Bian S; Shiu A; Chang EL; Sheng K; Yang W; Tuli R
    Phys Med Biol; 2020 Jun; 65(10):105012. PubMed ID: 32187583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arterial involvement and resectability scoring system to predict R0 resection in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation therapy.
    Noda Y; Pisuchpen N; Mercaldo ND; Sekigami Y; Michelakos T; Parakh A; Wo JY; Qadan M; Ferrone C; Lillemoe KD; Ryan DP; Clark JW; Fernandez-Del Castillo C; Hong TS; Kambadakone AR
    Eur Radiol; 2022 Apr; 32(4):2470-2480. PubMed ID: 34665317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan.
    Ei S; Takahashi S; Ogasawara T; Mashiko T; Masuoka Y; Nakagohri T
    Gut Liver; 2023 Sep; 17(5):698-710. PubMed ID: 36843421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.
    Sakaguchi T; Satoi S; Yamamoto T; Yamaki S; Sekimoto M
    Surg Today; 2020 Apr; 50(4):335-343. PubMed ID: 31993761
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study.
    van Veldhuisen E; Walma MS; van Rijssen LB; Busch OR; Bruijnen RCG; van Delden OM; Mohammad NH; de Hingh IH; Yo LS; van Laarhoven HW; van Leeuwen MS; Nio CY; van Santvoort HC; de Vries J; Wessels FJ; Wilmink JW; Molenaar IQ; Besselink MG; van Lienden KP;
    HPB (Oxford); 2019 Oct; 21(10):1385-1392. PubMed ID: 31010633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification.
    Gilbert JW; Wolpin B; Clancy T; Wang J; Mamon H; Shinagare AB; Jagannathan J; Rosenthal M
    Ann Oncol; 2017 Sep; 28(9):2067-2076. PubMed ID: 28407088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.